![]() ![]() Serial Assessment of Cardiac Biomarkers and Risk of Cardiovascular Death or Hospitalization for Heart Failure in DECLARE-TIMI 58 (Berg, AHA 2022) (Moura, AHA 2021)įibroblast Growth Factor-23, Cardiorenal Outcomes, and Efficacy of Dapagliflozin in Patients with T2DM-An analysis from DECLARE-TIMI 58 (Berg, ACC 2022)Īssessment of Atherothrombotic Risk in Patients with Type 2 Diabetes Mellitus (Berg, ACC 2022)Įffects of dapagliflozin on CV and kidney events by baseline eGFR and UACR in patients with T2DM-A patient-level pooled analysis of DECLARE-TIMI 58 and DAPA-CKD trials (Moura, ESC 2022) Influence of Cardiovascular Drugs on the Efficacy and Safety of Dapagliflozin Patients with Type 2 Diabetes Mellitus in DECLARE-TIMI 58 (Oyama, ESC 2021)ĭapagliflozin and Changes in Metabolic Syndrome in Patients with Type 2 Diabetes. Mediation Analysis for Dapagliflozin and the Reduction in Hospitalization for Heart Failure in DECLARE-TIMI 58 (Berg, ACC 2021) Relationship between cardiac biomarkers and major adverse cardiovascular events in DECLARE-TIMI 58 (Zelniker, AHA 2020) HF Risk Stratification and Efficacy of SGLT2 Inhibitors in Patients with T2DM (Berg, ESC 2019)ĭECLARE Dapa Biomarker (Zelniker, AHA 2019)ĭECLARE Efficacy in T2DM Poster (O’Donoghue, AHA 2019)Ī Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients with T2DM in DECLARE-TIMI 58 (Berg, AHA 2020)ĭevelopment of A Novel Biomarker-Based Risk Score for Heart Failure in Patients with Diabetes (Berg, AHA 2020)Ĭardiovascular Risk Stratification and Efficacy of Dapagliflozin on Cardiovascular Outcomes in Patients with T2DM in the DECLARE-TIMI 58 Trial (Oyama, AHA 2020) 2019 Jan 24 380(4):347-357.Įffect of dapa on HF in T2DM (Kato, LBCT, ACC 2019)ĭapa and Outcomes in Patients with PAD (Bonaca, ACC 2019)ĭapagliflozin and CV Outcomes in Patients with T2DM and Prior MI in DECLARE (Furtado, ACC 2019)ĭapa and CV Outcomes – Patients with T2DM According to Baseline Kidney Function and Albuminuria Status (Zelniker, ESC 2019) MAIN RESULTS: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes DECLARE-TIMI 58 was an event-driven trial. ![]() It randomized approximately 17,150 patients with type 2 diabetes mellitus and either known cardiovascular disease (secondary prevention cohort) or at least two risk factors for cardiovascular disease (primary prevention cohort). The trial also sought to definitively exclude unacceptable cardiovascular risk from dapagliflozin in these patients. DECLARE – TIMI 58 was a superiority trial and designed to test the hypothesis that in patients with type 2 diabetes mellitus long-term treatment with dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, will reduce one or both of the co-primary endpoints: (1) the incidence cardiovascular death, myocardial infarction, or ischemic stroke or (2) the incidence of cardiovascular death or hospitalization for heart failure. DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events) was a multi-national, randomized, double-blind, placebo-controlled Phase IIIB trial jointly led by the TIMI Study Group and Hadassah Medical Center, and sponsored by AstraZeneca and Bristol-Myers Squibb. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |